Aeolus Pharmaceuticals, Inc. (OTC Bulletin Board: AOLS) announced financial results for the three months and twelve months ended September 30, 2009. The Company reported a net loss of $746,000, or $0.02 per share, for the three months ended September 30, 2009 compared to a loss of $1,055,000, or $0.03 per share, for the three months [...]

Continue reading " Aeolus Pharmaceuticals Announces Fiscal Year 2009 Financial Results "

Biodel Inc. (Nasdaq: BIOD)reported financial results for the fourth quarter and fiscal year ended September 30, 2009.
Fourth Quarter and Fiscal Year 2009 Financial Results
Biodel reported a net loss for the quarter ended September 30, 2009 of $10.5 million, or $0.44 per share, compared to a net loss of $12.7 million, or $0.53 per share, for [...]

Continue reading " Biodel Reports Fourth Quarter and Fiscal Year 2009 Financial Results "

*Multiple Data Presentations at Upcoming AACR-NCI-EORTC, San Antonio Breast Cancer Symposium and ASH Meetings
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, announced financial results for the three-month period ended September 30, 2009 – the first quarter of the Company’s 2010 fiscal [...]

Continue reading " ImmunoGen, Inc. Reports First Quarter Fiscal Year 2010 Financial Results "

Current diagnostic tests for ovarian cancer are woefully ineffective for early detection of the disease, say researchers at Stanford University School of Medicine. A new study finds that in order to make a significant dent in the mortality rate for the deadly cancer, the tests would have to be able to detect tumors of less [...]

Continue reading " Ovarian Cancer Tests Flawed, in Need of New Design, Says Stanford Study "

Rhode Island Hospital is one of only four sites across the country to participate in a new clinical trial called the DIGNITY Study. The study will investigate the effectiveness of a chemotherapeutic agent, ThermoDox, used in conjunction with mild hyperthermia (a form of heat therapy) for treating recurrent chest wall breast cancer.

Related posts

Array BioPharma Reports [...]

Continue reading " Rhode Island Hospital First in Country to Enroll Patient in New National Study for Treating Recurrent Chest Wall Breast Cancer "

The Alpha-1 Foundation announced it will receive up to $1 million in grant matching funds from Talecris Biotherapeutics, Inc. to support research into alpha1-antitrypsin deficiency, a genetic condition in which low levels of the essential blood protein alpha1-proteinase inhibitor, can cause emphysema.

Related posts

Gilead Sciences Announces Agreement With Tibotec Pharmaceuticals to Develop and Commercialize New Fixed-Dose [...]

Continue reading " Alpha-1 Foundation Announces the Million Dollar Match Program Made Possible by a Talecris Biotherapeutics Grant "

Pfizer Inc announced the discontinuation of the SUN 1094 Phase 3 study that evaluated SUTENT (sunitinib malate) plus paclitaxel versus bevacizumab plus paclitaxel for the first line treatment of patients with advanced breast cancer. The independent Data Monitoring Committee (DMC) found that treatment with sunitinib in combination with paclitaxel would be unable to meet the [...]

Continue reading " Pfizer Discontinues SUN 1094 Trial of Sunitinib plus Paclitaxel in Advanced Breast Cancer "

Z-Cube Srl, the corporate venture arm of Zambon Company SpA, and Yissum Research Development Company Ltd., the technology transfer company of the Hebrew University of Jerusalem, announced that they have entered into a license agreement for Z-Cube to develop and commercialize an innovative nanotechnology drug delivery system for the treatment of pain. The technology was [...]

Continue reading " Z-Cube, the corporate venture arm of Zambon Company SpA, and Yissum Research Development Company Ltd. Sign a Licensing Agreement for the Development of an Innovative Nanotechnology Drug Delivery System for the Treatment of Pain "

Human immune cells communicate constantly with one another as they coordinate to fight off infection and other threats. Now researchers at Stanford University’s School of Medicine have shown that muffling a key voice in this conversational patter is an early step in the progression of human cancers. Silencing an inter-cell signaling mechanism called the interferon [...]

Continue reading " Disruption of Immune-System Pathway Key Step in Cancer Progression, Stanford Study Shows "

Hydra Biosciences, Inc., a biotech company developing novel ion channel drugs, announced that research published by Hydra Biosciences scientists and collaborators at Yale University for the first time identified the ion channel TRPA1 as playing an essential role in allergic asthma and demonstrated that Hydra’s TRPA1 antagonist HC-030031 effectively treated allergic asthma in mice. The [...]

Continue reading " Research published in PNAS by Hydra Biosciences is First Demonstration in Mammals that TRP Ion Channel Drug Can Treat Allergy-Induced Asthma "